JOINTstat® (14-3-3η) ELISA is indicated for use in conjunction with other serological and clinical assessments for the diagnosis of RA
Several studies have been conducted to describe the clinical significance of 14-3-3η levels along the continuum of care from pre-RA and diagnosis to prognosis and monitoring.
Early RA and Arthralgia
14-3-3η expression precedes an RA diagnosis by at least 5 years and is present in the earliest stages of RA. Learn More
Joint Damage Risk
A 14-3-3η positive test and levels above 0.4 ng/ml are associated with higher risk of joint damage progression, in early and established RA. Learn More
Changes in 14-3-3η Blood Levels
14-3-3η blood levels change along the course of the disease and treatment, corresponding with changes in clinical status. Learn More
Comments are closed.